Hydroxyurea in AML: Mechanism and Clinical Role
Hydroxyurea works in acute myeloid leukemia primarily as a cytoreductive agent for emergency management of hyperleukocytosis, not as definitive anti-leukemic therapy. It rapidly lowers white blood cell counts by inhibiting ribonucleotide reductase, thereby blocking DNA synthesis and preventing cell division 1.
Mechanism of Action
Hydroxyurea functions as an antimetabolite that inhibits ribonucleotide reductase, the enzyme responsible for converting ribonucleotides to deoxyribonucleotides—a critical step in DNA synthesis 2. By blocking this pathway, hydroxyurea prevents leukemic blast cells from replicating, leading to rapid cytoreduction. Recent research suggests an additional mechanism in MLL-rearranged AML involving matrix metallopeptidase 2 (MMP2) deficiency and iron chelation effects 3, though this remains investigational.
Clinical Application in AML
Emergency Cytoreduction for Hyperleukocytosis
The primary indication for hydroxyurea in AML is the emergency management of hyperleukocytosis (WBC >100,000/μL) to prevent leukostasis complications 1. Leukostasis can cause life-threatening hemorrhagic events, pulmonary infiltrates, retinal hemorrhages, and cerebral complications.
Recommended dosing is 50-60 mg/kg per day until WBC decreases to less than 10-20 × 10⁹/L 1. This approach effectively reduces blast counts by approximately 50% after a single dose 4. The European LeukemiaNet guidelines explicitly recommend hydroxyurea as the standard therapy to lower WBC in hyperleukocytosis, noting that while leukapheresis is an option, it has shown no impact on long-term outcome 1.
Pre-treatment Strategy
Evidence supports using hydroxyurea prior to intensive chemotherapy in hyperleukocytic AML. A retrospective study of 160 patients demonstrated that pre-treatment with oral hydroxyurea reduced hospital mortality (19% vs 34%, p=0.047) compared to emergency induction chemotherapy, even after adjusting for age and initial WBC count 5. This strategy allows safer initiation of definitive chemotherapy by reducing tumor burden.
Role in Non-Intensive Treatment
For elderly or unfit patients, hydroxyurea serves as a palliative cytoreductive agent alongside best supportive care 6. However, low-dose cytarabine is superior to hydroxyurea for achieving remissions in this population (18% vs 1% CR rate, p=0.00006) 7. Therefore, hydroxyurea should be reserved for symptom control rather than as primary therapy in unfit patients.
Venetoclax-Based Regimens
In modern AML treatment with venetoclax combinations, hydroxyurea is recommended to achieve WBC <25,000/μL prior to initiating venetoclax with hypomethylating agents or low-dose cytarabine 8. This prevents tumor lysis syndrome during venetoclax dose escalation.
Important Limitations and Caveats
Not Definitive Therapy
Hydroxyurea provides only transient blast reduction and does not induce complete remissions in AML 1. It must be followed by definitive chemotherapy or other disease-modifying treatment. The drug is explicitly contraindicated as monotherapy for curative intent.
Toxicity Profile
Hydroxyurea causes dose-dependent myelosuppression affecting all cell lines 2. A critical dose-related toxicity is mucositis: high-dose hydroxyurea (≥75 mg/kg/day) significantly increases grade 3-4 mucositis (28.6% vs 0%, p=0.002) and narcotic requirements compared to lower doses 9. This supports using the lower end of the dosing range (50 mg/kg/day) when possible.
Leukemogenic Potential
While hydroxyurea is FDA-approved for chronic myeloid leukemia 2, there are concerning reports of AML development in patients receiving prolonged hydroxyurea therapy for other conditions 10, 11. However, in the acute AML setting where hydroxyurea is used briefly for cytoreduction, this risk is not clinically relevant.
Renal Dosing
Reduce hydroxyurea dose by 50% in patients with creatinine clearance <60 mL/min or end-stage renal disease 2. On dialysis days, administer after hemodialysis with close hematologic monitoring.
Practical Algorithm
- Identify hyperleukocytosis: WBC >100,000/μL with or without leukostasis symptoms
- Initiate hydroxyurea: 50-60 mg/kg/day orally (adjust for renal function)
- Monitor: Daily CBC, target WBC <10-20 × 10⁹/L
- Prevent tumor lysis: Aggressive hydration, allopurinol or rasburicase, monitor electrolytes
- Transition: Once WBC controlled, proceed immediately to definitive induction chemotherapy
- Duration: Discontinue hydroxyurea once definitive therapy initiated—typically 1-3 days of use
The key principle is that hydroxyurea buys time to safely initiate definitive therapy but is never a substitute for it 1, 12.